electroCore Announces Acacia Clinics And The Vagus Nerve Society Launch New Research Initiative To Mull Gammacore Sapphire Use As Treatment For Symptoms Associated With PTSD

electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD.

The study entitled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder," will be led by Danielle DeSouza MSc, PhD, VP of Research at Acacia Clinics ("the Investigator"). The study will collect data on the safety and effectiveness of gammaCore Sapphire as an adjunctive treatment for the symptoms of PTSD. The primary safety measure for this study is the incidence and occurrence of significant adverse events (SAEs) related to nVNS treatment, while the primary efficacy outcome is the difference from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at the 12-week treatment period (versus baseline/4-week run-in period). The CAPS-5 is a semi-structured clinical interview administered by the Investigator and is used to assess index history of DSM-5 defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of post-traumatic stress symptoms, as evidenced by CAPS-5 total score. The CAPS-5 provides diagnostic status (presence versus absence) of PTSD as well as PTSD symptom severity. A secondary efficacy outcome will include the difference in the PTSD Checklist (PCL-5) score, a 20-item self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms derived from the DSM-5 symptoms of PTSD, and clinical improvement with the Clinical Global Index (CGI) at the 12-week treatment period (versus baseline).